Centessa Pharmaceuticals shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $4 to $11.
Portfolio Pulse from Benzinga Newsdesk
Centessa Pharmaceuticals' stock (CNTA) is trading higher following an upgrade from Jefferies, moving from a Hold to a Buy rating, with the price target also increased from $4 to $11.
November 15, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies upgraded Centessa Pharmaceuticals from Hold to Buy and raised the price target from $4 to $11, indicating a positive outlook on the stock.
The upgrade by Jefferies to a Buy rating, along with a significant increase in the price target, suggests a strong vote of confidence in Centessa Pharmaceuticals' prospects. This is likely to be viewed positively by investors and could lead to a short-term increase in the stock price as market sentiment improves.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100